Genesis Molecular AI

Genesis Molecular AI is a private biotech company developing small molecule medicines using an AI- and physics-driven drug discovery platform. The company combines proprietary foundation models, including Pearl, with its GEMS platform to generate, predict, and optimize molecules against difficult biological targets. Genesis runs both internal programs and partnered discovery efforts, with disclosed collaborations including Gilead and Incyte. Its disclosed internal pipeline spans oncology and immunology, with a lead effort focused on pan-mutant allosteric PIK3CA inhibitors and additional work on apoptosis-related and autoimmune targets. The company appears positioned as a molecular AI platform business that is advancing toward development candidate nomination rather than clinical-stage development.